Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax's vaccine will likely be approved by the FDA relatively soon, but NVAX stock is still facing many obstacles. The post Novavax Stock Can Rally, But It's Still Facing Many Obstacles appeared first on InvestorPlace.

Novavax Stock Can Rally, But It's Still Facing Many Obstacles

Arriving more than two years into the pandemic, here's what Novavax could bring to the immunity table in the US.

Novavax: Could It Change the COVID Vaccine Game?

Moderna

Novavax and Moderna both are betting on the booster market.

Could This News From Moderna Mean Trouble for Novavax?

The Australian regulatory authority has conditionally approved Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over. The provisional registration was based on data from Novavax's Phase 2 trial conducted.

Novavax' Sees Conditional Approval Of COVID-19 Vaccine Booster In Australia As US FDA Delays Its Decision

In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine history GAITHERSBURG, Md. , June 13, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Australian Therapeutic Goods Administration (TGA) has granted provisional registration of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over.

Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over

Investors may have to wait a bit longer for the big regulatory decision.

Should You Worry About Novavax's Latest Delay?

AbbVie

Pfizer

Should investors be keeping an eye on these movers in the biotech space?

Top Biotech Stocks To Invest In Today? 3 To Watch This Week

Can this beaten-down vaccine stock make a big comeback?

Novavax Stock: Bull vs. Bear

Lovesac Company

Pubmatic

Redfin

These highly innovative growth stocks are begging to be bought by opportunistic investors.

5 Cutting-Edge Growth Stocks That Can Turn $200,000 Into $1 Million by 2030

Ginkgo Bioworks Holdings

Novocure

Huge rebounds could be in store for these beaten-down stocks.

3 Stocks Down 50% or More That You Can Buy Right Now

There was some bad news on the regulatory front for the vaccine specialist.

Why Novavax Stock Plummeted on Thursday

Novavax Inc (NASDAQ: NVAX) shares are trading lower Thursday following reports that the U.S. Food and Drug Administration's decision on the company's COVID-19 vaccine could be delayed to review manufacturing changes. According to a CNBC report, citing an agency spokesperson,.

Why Novavax Stock Is Falling Today

Novavax's Covid-19 vaccine, unlike the Pfizer and Moderna ones, uses a well-established, protein-based approach.

Novavax Won't Get Authorization Until FDA Reviews Manufacturing Changes

The FDA's committee recommended the Novavax vaccine for use in the U.S. on Tuesday.

FDA decision on Novavax's Covid shots could be delayed to review changes in manufacturing

Novavax still has big hurdles to jump over.

Why Investors Yawned at Novavax's Great FDA Panel News

An FDA advisory committee supports granting emergency use authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. Post the news, the stock rallies 20% in pre-market trading.

FDA Committee Proposes EUA Nod to Novavax's (NVAX) COVID Jab

Novavax and its COVID vaccine Nuvaxovid was once thought to be a serious challenger to be the first approved COVID vaccine in the US. Yesterday, nearly 550 days after Pfizer / BioNTech's >$50bn selling Comirnaty vaccine won an EUA, Nuvaxovid was recommended for the same by an FDA Adcomm.

Novavax: EUA Win Reinforces More Positive Outlook For Vaccine Dark Horse

Novavax, Inc (NASDAQ: NVAX) gapped up 10% to start the trading day on Wednesday, but at press time, the stock had given back almost all of its gains to trade mostly flat. The pharmaceutical company's NVX-CoV2373 COVID-19 vaccine was recommended for Emergency Use Authorization for individuals.

Here's What To Watch On Novavax Stock As Latest COVID-19 Vaccine Gains Approval

The BA.4 and BA.5 subvariants of the highly transmissible omicron variant of the coronavirus that causes COVID-19 are spreading rapidly, according to data from the Centers for Disease Control and Prevention, raising concern that they may overtake others to dominate in the U.S.

New omicron subvariants are rising in U.S., and FDA panel gives its backing to Novavax vaccine

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?

Why Is Novavax (NVAX) Down 11.7% Since Last Earnings Report?

Novavax's Covid-19 vaccine is protein-based; others use messenger RNA to boost immunity to the virus.

Novavax Should Get Pop From Final FDA Signoff, JPMorgan Says

NVAX stock price predictions are in the spotlight after its vaccine got an unanimous recommendation from the FDA's advisory panel yesterday. The post NVAX Stock Price Predictions: Where Will Novavax Go From Here?

NVAX Stock Price Predictions: Where Will Novavax Go From Here?

An FDA decision may come in a matter of days.

Novavax Won a Nod From FDA Advisors. Now What?

Novavax (NVAX) stock is on the move Wednesday as investors react to an update from the FDA about its Covid-19 vaccine for adults. The post Is NVAX Stock a Buy?

Is NVAX Stock a Buy? What 3 Pros Say About Novavax Now.

After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ: NVAX) can now heave a sigh of relief. Adcom Unanimously Back Novavax: FDA's Vaccines and Related Biological Products Advisory Committee that reviewed.

News for Novavax Stock (NVAX)